Cantor Fitzgerald Predicts Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Verastem in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the biopharmaceutical company will post earnings of ($3.24) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share.

VSTM has been the subject of several other reports. BTIG Research boosted their target price on Verastem from $13.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Mizuho upped their price objective on Verastem from $7.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, December 19th. Guggenheim initiated coverage on Verastem in a report on Monday, September 30th. They issued a “buy” rating and a $13.00 price target on the stock. Royal Bank of Canada upped their target price on Verastem from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Verastem in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.38.

Verastem Stock Up 2.4 %

Shares of NASDAQ VSTM opened at $5.52 on Thursday. The business has a 50-day moving average of $4.88 and a two-hundred day moving average of $3.61. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. Verastem has a 1 year low of $2.10 and a 1 year high of $14.22.

Verastem (NASDAQ:VSTM) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.11.

Institutional Investors Weigh In On Verastem

Hedge funds have recently bought and sold shares of the business. FMR LLC acquired a new stake in shares of Verastem during the third quarter worth approximately $41,000. SG Americas Securities LLC bought a new stake in shares of Verastem in the 3rd quarter worth about $43,000. JPMorgan Chase & Co. lifted its position in shares of Verastem by 55.4% during the third quarter. JPMorgan Chase & Co. now owns 16,878 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 6,016 shares during the last quarter. Apollon Wealth Management LLC increased its holdings in Verastem by 104.6% in the third quarter. Apollon Wealth Management LLC now owns 20,457 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 10,457 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Verastem by 4,172.0% during the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 28,119 shares in the last quarter. Institutional investors and hedge funds own 88.37% of the company’s stock.

Insider Buying and Selling at Verastem

In other news, CEO Dan Paterson sold 8,568 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $5.24, for a total transaction of $44,896.32. Following the completion of the sale, the chief executive officer now directly owns 347,581 shares in the company, valued at $1,821,324.44. This trade represents a 2.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 10,321 shares of company stock valued at $52,217 over the last 90 days. 2.20% of the stock is owned by corporate insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.